Adverse Drug Reactions Reporting Profile in Tertiary Referral Hospital: A Retrospective Pharmacovigilance Study in Indonesia
Downloads
Background: Pharmacovigilance is administered to several pharmacological classes of drugs worldwide. However, there are still insufficient data regarding the prevalence and general characteristics of drug reactions, especially in developing countries. Objective: This study aimed to determine the prevalence and characteristics of ADRs, including the pharmacological class involved, and report and classify the clinical manifestations associated with ADRs. Methods: This retrospective study was based on patient ADR reports during observation. Prevalence, patient demographics, and other data were evaluated using descriptive statistics. Results: Of 773 reports that met the inclusion criteria, most were doctors (80.6%), followed by pharmacists (18.7%). Of the total cases, 430 (55.6%) occurred in the women. Most suspected ADRs occurred in the 19-60 years age group (583; 75.4%). The highest incidence of ADR was observed in patients using antineoplastic agents (19.5%), systemic antibacterials (16.4%), or antihypertensives (12.5%). The majority of clinical manifestations were gastrointestinal disorders (41.7%), and approximately 309 (40%) ADR cases continued with antagonists/antidotes. Approximately 62% of the patients who experienced ADRs recovered. Conclusion: Antineoplastic, systemic antibacterial, and antihypertensive drugs appeared to be the most common drugs used for suspected ADR cases in this hospital. ADR reporting has been running well, but not all healthcare workers have participated actively. Hopefully, the results of this research will contribute to the upcoming strategies for pharmacovigilance activities in this hospital and other healthcare facilities to improve the quality and quantity of ADR reporting and increase the safety of medication usage.
Aagaard, L., Strandell, J., Melskens, L., Petersen, P.S.G. Hnsen, H.H. and (2012) ‘Global patterns of adverse drug reactions over a decade: Analyses of Spontaneous Reports to VigibaseTM’, Drug Safety, 35(12), pp. 1171–1182. https://doi.org/10.2165/11631940-000000000-00000
Adu-Gyamfi, P.K.T., Mensah, K.B., Ocansey, J., Moomin,A., Danso, B.O., Agtapong, F. and Arthur-Mensah Jr, R . (2022) ‘Assessment of knowledge, practices, and barriers to pharmacovigilance among nurses at a teaching hospital, Ghana: A cross-sectional study', BMC Nursing, 21(1), pp. 1–9. https://doi.org/10.1186/s12912-022-00965-4
Al-Worafi, Y.M., , Kassab, Y.W., Alseragi ,W.M. , Almutairi, M.S., Ahmed, A., Ming, L.C., Alkhoshaiban, A.S. and Hadi, M.A. (2017) ‘Pharmacovigilance and adverse drug reaction reporting: A perspective of community pharmacists and pharmacy technicians in Sana’a, Yemen, ’ Therapeutics and Clinical Risk Management, 13, pp.1175–1181. https://doi.org/10.2147/TCRM.S140674
Almasdy, D., Sari, Y.O., Ilahi, H.T. and Kurniasih, N. (2018) ‘Pengembangan Instrumen Pemantauan Efek Samping Obat: Efek Samping Obat Pada Pasien Strok Iskemik’, Jurnal Sains Farmasi & Klinis, 5(3), pp. 225–232.
BPOM RI (2012) Pedoman Monitoring Efek Samping Obat (MESO) Bagi Tenaga Kesehatan, Direktorat Pengawasan Distribusi Produk Terapetik dan PKRT Badan Pom RI.
BPOM RI (2019) ‘Farmakovigilans (Keamanan Obat) : Panduan Deteksi dan Pelaporan Efek Samping Obat Untuk Tenaga Kesehatan’, Pusat Farmakovigilans Nasional, pp. 1–26.
BPOM RI (2022) ‘Badan pengawas obat dan makanan No. 12 Tahun 2022 Tentang Pedoman Cara Pembuatan Obat yang Baik di Rumah Sakit’, Bpom Ri, 11(1), pp. 1–16.
BPOM RI (2023) ‘Buletin Berita Monitoring Efek Samping Obat.’
Corsonello, A., Pedone, C. and Incalzi, R. (2010) ‘Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions,’ Current Medicinal Chemistry, 17(6), pp. 571–584. https://doi.org/10.2174/092986710790416326
Davies, E.C., Green, C,F,, Taylor, S,, Williamson, P,R,, Mottram, D,R, and Pirmohamed, M. (2009) ‘Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes’, PLoS ONE, 4(2). https://doi.org/10.1371/journal.pone.0004439
Ferner, R. and Aronson, J. (2019) ‘Susceptibility to adverse drug reactions’, British Journal of Clinical Pharmacology, 85(January), pp. 2205–2212. https://doi.org/10.1111/bcp.14015
GarcÃa-Abeijon et al. (2023) ‘Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update’, Drug Safety, 46(7), pp. 625–636. https://doi.org/10.1007/s40264-023-01302-7
Giardina, C., Costa, C., Taracido, M., Herdeiro,M.T. Torre ,C. and Figueiras, A. (2018) ‘Adverse drug reactions in hospitalized patients: Results of the FORWARD (facilitation of reporting in hospital ward) study’, Frontiers in Pharmacology, 9(APR), pp. 1–12. https://doi.org/10.3389/fphar.2018.00350
Gupta, A., Kaur, A., Shukla, P.and Chhabra, H. (2017) ‘Adverse Drug Reactions Pattern in a Tertiary Level Teaching Hospital: A Retrospective Study’, Indian Journal of Pharmacy Practice, 10(1), pp. 27–31. https://doi.org/10.5530/ijopp.10.1.7
Indriani, L., Rokhmah, N.N. and Shania, N. (2022) ‘Penilaian Efektivitas Antihipertensi dan Efek Samping Obat di RSUP Fatmawati’, Jurnal Sains Farmasi & Klinis, 9(sup), p. 146. https://doi.org/10.25077/jsfk.9.sup.146-151.2022
Ingrand, I., Defossez, G., Lafay-Chebassier, C., Chavant, F., Ferru, A., Ingrand, P. and Pérault-Pochat, M-C. (2020) ‘Serious adverse effects after chemotherapy: A general cancer registry-based incidence survey. British Journal of Clinical Pharmacology, 86(4), pp. 711–722. https://doi.org/10.1111/bcp.14159
Keche, Y., Gaikwad, N. and Dhaneria, S. (2021) ‘Preventability, predictability, severity and causality assessment of adverse drug reactions reported from a teaching hospital in chhattisgarh: A retrospective analysis’, Journal of Family Medicine and Primary Care, 10(7). https://doi.org/10.4103/jfmpc.jfmpc_2374_20
Melani, R., Darmawan, E. and Raharjo, B. (2019) ‘Gambaran Hubungan Regimen Dosis Danefek Samping Kemoterapi pada Pasien Kanker di RSUD Prof Dr. Margono Soekarjo Purwokerto Periode Bulan Januari-Februari Tahun 2019’, Majalah Farmaseutik, 15(2), p. 113. https://doi.org/10.22146/farmaseutik.v15i2.47664
Al Meslamani, A.Z. (2023) ‘Underreporting of adverse drug events: A look into the intent, causes, and potential solutions, Expert Opinion on Drug Safety, 22(5), pp. 351–354. https://doi.org/10.1080/14740338.2023.2224558
Montastruc, J.L., Lafaurie, M., de Canecaude, C., Durrieu, G., Sommet, A., Montastruc, F. and Bagheri, H (2021) ‘Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database. British Journal of Clinical Pharmacology, 87(11), pp. 4334–4340. https://doi.org/10.1111/bcp.14851
Permata, A. and Azmi, R.N. (2024) ‘Analisis Faktor Risiko Kejadian Adverse Drug Reaction Obat Anti Inflamasi Non Steroid pada Pasien Gout’, Pharmaceutical Journal of Indonesia, 21(1), pp. 1–5.
Pertiwi, M. Y., Wardani, I. S. and Wedayani, A.. A.N. (2021) ‘Profil Efek Samping Penggunaan Antiretroviral Pada Penderita HIV/AIDS Di Poliklinik VCT di Kota Mataram Tahun 2019’, Unram Medical Journal, 9(4), pp. 292–299. https://doi.org/10.29303/jku.v9i4.443
Rini, V. A., Ikawati, Z. and Perwitasari, D. A. (2014) ‘Pengaruh Pemantuan Apoteker Terhadap Keberhasilan Terapi Dan Kualitas Hidup Pasien Tuberkulosis’, Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), 4(3), pp. 185–192.
Tadge, S., Gambhire, M. and Kulkarni, A. (2023) ‘A Narrative Review on Adverse Drug Reactions Reporting : Current Practices and Challenges’, Clinical Journal of Pharmacology and Pharmacotherapeutics, 2, pp. 3–7.
Wang, G. and Akbar, W. (2016) ‘Knowledge, attitudes, and practice of pharmacovigilance among healthcare professionals in Indonesia. Health Science Journal of Indonesia, 7(1), pp. 59–63. https://doi.org/10.22435/hsji.v7i1.5285.59-63
Watson, S., Caster, O., Rochon, P.A. and den Ruijter, H. (2019) ‘Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century’, EClinicalMedicine, 17, p. 100188. https://doi.org/10.1016/j.eclinm.2019.10.001
Yadesa T.M., Kitutu F.E., Deyno S., Ogwang, P.E., Tamukang, R. and Alele, P.E. (2021) ‘Prevalence, characteristics, and predicting risk factors of adverse drug reactions among hospitalized older adults: A systematic review and meta-analysis. SAGE Open Medicine, 9. https://doi.org/10.1177/20503121211039099
Yadesa T.M., Kitutu F.E., Tamukong R. and Alele, P.E (2021) ‘Prevalence, incidence, and characteristics of adverse drug reactions among older adults hospitalized at the mbarara regional referral hospital, Uganda: A prospective cohort study, Clinical Interventions in Aging, 16(September), pp. 1705–1721. https://doi.org/10.2147/CIA.S332251
Yosmar, R., Inanta, N.P. and Sari, Y.O. (2018) ‘Studi Prospektif Adverse Drug Reactions (ADRS) Obat Hipoglikemik Oral Terhadap Pasien Diabetes Mellitus Tipe 2 di Suatu Rumah Sakit, Padang’, Jurnal Sains Farmasi & Klinis, 5(3), pp. 169–175. Available at: http://jsfk.ffarmasi.unand.ac.id
Zucker, I. and Prendergast, B.J. (2020) ‘Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology of Sex Differences, 11(1), pp. 1–14. https://doi.org/10.1186/s13293-020-00308-5
Copyright (c) 2024 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. The copyright of this journal belongs to the Editorial Board and Journal Manager with the author's knowledge, while the moral right of the publication belong to the author.
2. The formal legal aspect of journal publication accessibility refers to the Creative Commons Attribution-Non-Commercial-Share Alike (CC BY-NC-SA), which implies that the publication can be used for non-commercial purposes in its original form.
3. Every publication (print/electronic) is open access for educational, research, and library purposes. In addition to the objectives mentioned above, the editorial board is not responsible for copyright infringement
.jpg)
